RENO yields 2000000.00% · ABBV yields 3.06%● Live data
📍 RENO pulled ahead of the other in Year 1
Combined, RENO + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of RENO + ABBV for your $10,000?
Renovare Environmental, Inc., through its subsidiaries, provides environmental management solutions worldwide. The company's suite of technologies includes on-site biological processing equipment for food waste, patented processing facilities for the conversion of municipal solid waste into renewable fuel, and proprietary real-time data analytics tools to reduce food waste generation. It markets Revolution Series Digesters, an aerobic digestion technology solution for the disposal of food waste at the point of generation; and Mechanical Biological Treatment technology to process waste at the municipal or enterprise level. The company serves retail, healthcare, government, hospitality, education, food service, and other sectors, as well as food distributors, convention centers, hotels, restaurants, stadiums, municipalities, and academic institutions. The company was formerly known as BioHiTech Global, Inc. and changed its name to Renovare Environmental, Inc. in December 2021. Renovare Environmental, Inc. is headquartered in Chestnut Ridge, New York.
Full RENO Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.